Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study - Université Paris-Est-Créteil-Val-de-Marne Access content directly
Journal Articles Lung Cancer Year : 2020

Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study

Jesus Corral Jaime
  • Function : Author

Domains

Cancer
Fichier principal
Vignette du fichier
PIIS0169500220305067.pdf (838.48 Ko) Télécharger le fichier
Origin : Publication funded by an institution

Dates and versions

hal-04143081 , version 1 (27-06-2023)

Identifiers

Cite

Marina Chiara Garassino, Byoung-Chul Cho, Joo-Hang Kim, Julien Mazières, Johan Vansteenkiste, et al.. Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study. Lung Cancer, 2020, 147, pp.137 - 142. ⟨10.1016/j.lungcan.2020.06.032⟩. ⟨hal-04143081⟩
8 View
14 Download

Altmetric

Share

Gmail Facebook X LinkedIn More